Zeltia: Report at 31 December 2005
Zeltia s.a.
Zeltia: Report at 31 December 2005
MADRID, February 23 /PRNewswire/ --
Group:
- Capital increase at Zeltia. The placement of 10.75 million new shares among
qualified international investors raised 65 million euro
- R&D expenditure up 24
- Net revenues in 2005: 72 million euro - Net cash position at 31 December 2005: 93
million euro net of short-term financial debt and 51 million euro net of total financial
debt PharmaMar:
- Yondelis(R):
- Phase III pivotal trial on ovarian cancer commenced - Recruitment for the pivotal
randomised trial on soft-tissue sarcoma was completed - Aplidin(R):
- Phase II studies on prostate and bladder cancer commenced - Combination studies with
other chemotherapy agents commenced - Zalypsis(R), PharmaMar's fifth compound to reach
clinical trials - PM02734 is PharmaMar's sixth compound to reach clinical trials Xylazel:
- Launched a full range of Xylazel-brand wood protecting paints and varnishes.
- Conclusion of licensing and marketing agreement with ICI.
Isabel Lozano
Chief Executive Officer
PHARMAMAR, S.A.
C/ Reyes, 1.
Colmenar Viejo Madrid
Telephone +34-91-846-60-00
Catherine Moukheibir
Head of Capital Market Strategy
ZELTIA, S.A.
José Abascal, 2. Madrid
Telephone +34-91-444-45-00
Ma Luisa de Francia
Chief Financial Officer
ZELTIA, S.A.
José Abascal, 2. Madrid
Telephone +34-91-444-45-00
For a copy of the full results, please refer to www.zeltia.com